The IL-8/CXCR1/2 axis has emerged as a critical target in cancer therapy due to its multifaceted roles in tumor growth, angiogenesis, metastasis, and immune suppression (CXCR1/2 inhibitors, Table 2, Figure 2). The gene discussed is CXCL8; the disease is neoplasm.